These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 21704406)

  • 41. Cytotoxic and radiosensitizing effects of FAK targeting in human glioblastoma cells in vitro.
    Storch K; Sagerer A; Cordes N
    Oncol Rep; 2015 Apr; 33(4):2009-16. PubMed ID: 25625667
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Inhibition of radiation induced migration of human head and neck squamous cell carcinoma cells by blocking of EGF receptor pathways.
    Pickhard AC; Margraf J; Knopf A; Stark T; Piontek G; Beck C; Boulesteix AL; Scherer EQ; Pigorsch S; Schlegel J; Arnold W; Reiter R
    BMC Cancer; 2011 Sep; 11():388. PubMed ID: 21896192
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hypoxia Mediates Differential Response to Anti-EGFR Therapy in HNSCC Cells.
    Wiechec E; Hansson KT; Alexandersson L; Jönsson JI; Roberg K
    Int J Mol Sci; 2017 Apr; 18(5):. PubMed ID: 28468237
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combination of anti-HER3 antibody MM-121/SAR256212 and cetuximab inhibits tumor growth in preclinical models of head and neck squamous cell carcinoma.
    Jiang N; Wang D; Hu Z; Shin HJ; Qian G; Rahman MA; Zhang H; Amin AR; Nannapaneni S; Wang X; Chen Z; Garcia G; MacBeath G; Shin DM; Khuri FR; Ma J; Chen ZG; Saba NF
    Mol Cancer Ther; 2014 Jul; 13(7):1826-36. PubMed ID: 24748655
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Reduced proliferation and colony formation of head and neck squamous cell carcinoma (HNSCC) after dual targeting of EGFR and hedgehog pathways.
    Liebig H; Günther G; Kolb M; Mozet C; Boehm A; Dietz A; Wichmann G
    Cancer Chemother Pharmacol; 2017 Feb; 79(2):411-420. PubMed ID: 28110457
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
    Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab.
    Niehr F; Weichert W; Stenzinger A; Budach V; Tinhofer I
    J Transl Med; 2015 Apr; 13():106. PubMed ID: 25890004
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk.
    Yoshida T; Okamoto I; Okabe T; Iwasa T; Satoh T; Nishio K; Fukuoka M; Nakagawa K
    Int J Cancer; 2008 Apr; 122(7):1530-8. PubMed ID: 18033688
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Does dexamethasone inhibit anticancer activity of cetuximab in squamous cell carcinoma cell lines of the head and neck?
    Wagenblast J; Baghi M; Mörtel S; Hirth D; Thron L; Arnoldner C; Gstöttner W; May A; Hambek M
    Oncol Rep; 2009 Jul; 22(1):171-6. PubMed ID: 19513520
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dual inhibition of focal adhesion kinase and epidermal growth factor receptor pathways cooperatively induces death receptor-mediated apoptosis in human breast cancer cells.
    Golubovskaya V; Beviglia L; Xu LH; Earp HS; Craven R; Cance W
    J Biol Chem; 2002 Oct; 277(41):38978-87. PubMed ID: 12167618
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeting of EGFR and HER2 with therapeutic antibodies and siRNA: a comparative study in glioblastoma cells.
    Wichmann H; Güttler A; Bache M; Taubert H; Rot S; Kessler J; Eckert AW; Kappler M; Vordermark D
    Strahlenther Onkol; 2015 Feb; 191(2):180-91. PubMed ID: 25159136
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Anti-tumor effect of a novel FAK inhibitor TAE226 against human oral squamous cell carcinoma.
    Kurio N; Shimo T; Fukazawa T; Okui T; Hassan NM; Honami T; Horikiri Y; Hatakeyama S; Takaoka M; Naomoto Y; Sasaki A
    Oral Oncol; 2012 Nov; 48(11):1159-70. PubMed ID: 22766511
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cetuximab-resistant oral squamous cell carcinoma cells become sensitive in anchorage-independent culture conditions through the activation of the EGFR/AKT pathway.
    Ohnishi Y; Yasui H; Kakudo K; Nozaki M
    Int J Oncol; 2015 Dec; 47(6):2165-72. PubMed ID: 26497980
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dual "mAb" HER family blockade in head and neck cancer human cell lines combined with photon therapy.
    Guy JB; Méry B; Ollier E; Espenel S; Vallard A; Wozny AS; Simonet S; Lauret A; Battiston-Montagne P; Ardail D; Alphonse G; Rancoule C; Rodriguez-Lafrasse C; Magné N
    Sci Rep; 2017 Sep; 7(1):12207. PubMed ID: 28939847
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Concurrent cetuximab, cisplatin, and radiation for squamous cell carcinoma of the head and neck in vitro.
    Zhang N; Erjala K; Kulmala J; Qiu X; Sundvall M; Elenius K; Grénman R
    Radiother Oncol; 2009 Sep; 92(3):388-92. PubMed ID: 19447510
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inhibition of epithelial-mesenchymal transition by cetuximab via the EGFR-GEP100-Arf6-AMAP1 pathway in head and neck cancer.
    Matsumoto Y; Sakurai H; Kogashiwa Y; Kimura T; Matsumoto Y; Shionome T; Asano M; Saito K; Kohno N
    Head Neck; 2017 Mar; 39(3):476-485. PubMed ID: 27880014
    [TBL] [Abstract][Full Text] [Related]  

  • 57. 111In-cetuximab-F(ab')2 SPECT imaging for quantification of accessible epidermal growth factor receptors (EGFR) in HNSCC xenografts.
    van Dijk LK; Hoeben BA; Stegeman H; Kaanders JH; Franssen GM; Boerman OC; Bussink J
    Radiother Oncol; 2013 Sep; 108(3):484-8. PubMed ID: 23932156
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Insulin-like growth factor 1 receptor mediated tyrosine 845 phosphorylation of epidermal growth factor receptor in the presence of monoclonal antibody cetuximab.
    Iyer G; Price J; Bourgeois S; Armstrong E; Huang S; Harari PM
    BMC Cancer; 2016 Oct; 16(1):773. PubMed ID: 27716204
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The hypoxic tumor microenvironment and drug resistance against EGFR inhibitors: preclinical study in cetuximab-sensitive head and neck squamous cell carcinoma cell lines.
    Boeckx C; Van den Bossche J; De Pauw I; Peeters M; Lardon F; Baay M; Wouters A
    BMC Res Notes; 2015 Jun; 8():203. PubMed ID: 26032726
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inactivation of HNSCC cells by 90Y-labeled cetuximab strictly depends on the number of induced DNA double-strand breaks.
    Saker J; Kriegs M; Zenker M; Heldt JM; Eke I; Pietzsch HJ; Grénman R; Cordes N; Petersen C; Baumann M; Steinbach J; Dikomey E; Kasten-Pisula U
    J Nucl Med; 2013 Mar; 54(3):416-23. PubMed ID: 23345302
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.